Background: Breast cancer is the most common cancer among women, and its survival rate has improved. As the number of cancer survivors increases, it is important to support their social comeback during and after treatment.
Introduction
The importance of continuing to work during and after treatment of cancer is not only economical but is also about maintaining the motivation to live (1) . The importance of continuing to work for cancer patients and their families was highlighted in The Basic Plans to Promote Anti-Cancer Measures in Japan (2) and is an issue that needs to be addressed nationally.
However, the comprehensive investigation about the influence of cancer and cancer treatment on work in Japan is limited. According to the research by the Japanese Ministry of Health, Labour and Welfare, 30% of workers who were diagnosed with cancer retired voluntary and 4% were dismissed (3). The report did not consider the details such as sorts of cancer or cancer treatment, timing of quitting and characteristics of employment status.
There are several reasons that we focused on the employment issues of breast cancer (BC) patients or survivors in this study. First, BC is the most frequent cancer type among women (4) . More than 75 000 women were newly diagnosed as BC per year in Japan (4) . Second, most of the BC patients are women which indicates that the working situation is different from men. For example, the proportion of non-regular workers is quite higher in women workers than men (5) . Moreover, there is a report about the factors to less likely return to work among Japanese cancer survivors. The study concludes non-regular employed, patients with poor health, advancedstage tumors, of advanced age and women were the factors (6) . Thus, there is a possibility that BC patients' employment circumstance and problems are different from other cancer survivor's ones. Third, survival rates of BC are continuing to improve. The 10-year survival rate of Japanese patients with BC of any stage has reached more than 70% (7) . Fourth, the incident rate, by age group, begins to rise in people in their 30s and reaches its peak in people in their 40s (8) , the generations assume prominent roles both at home and in society. Taking account of these situations, it is important to support patients with BC so they can have a fulfilling professional and social life during and after treatment.
According to the researches in other countries, BC survivors who return to work need sick leave about 11 months in median duration (9) (10) (11) . Factors positively or negatively influencing the returning work of BC survivors have been reported in many studies, predominantly in North America and Europe. The analysis of sociodemographic factors such as age and education, treatment factors such as endocrine and radiation therapy and the type of surgery has revealed inconsistent results (9, (11) (12) (13) . In contrast, the influence of chemotherapy has been proven to be pivotal to negatively affecting for returning work (9, 10, 14) . However, currently, in clinical setting, most of the BC patients were treated by multidisciplinary treatment, not only by surgery or by medicine. To construct a simple and effective approach to support BC patients and survivors about employment, we hypothesize that consulting according to each treatment combination course might be useful. Concretely, in this study, we categorized the patients according to therapy combination which frequently performed in clinical setting; a group who underwent only local therapy, a group who underwent local therapy and endocrine therapy and a group who underwent chemotherapy in addition to other therapies.
Furthermore, we also investigated the employment status of advanced and metastatic BC patients. It is indicated that the issue about employment of those patients is quite different and more serious compared with early BC patients (15, 16) ; however, there is less study about this population especially in our country. The 5-year relative survival rate of the patients primary diagnosed as metastatic BC reached 33.7% in Japan (4) which indicates that there is comparatively long life even after the diagnosis of metastasis. Therefore, it is important to clarify the employment issues of these patients.
Our study aimed to reveal the details about employment of Japanese BC patients including primary and metastatic stages for considering the usefulness of supporting approach according to typical combinations of treatments.
Materials and methods

Study sample and data collection
Anonymous questionnaires were distributed to BC patients treated or followed up in the outpatient department of Aichi Cancer Canter Hospital between June and November 2014. Patients returned completed questionnaires by postal mail.
Inclusion criteria were as follows: (i) employed at the diagnosis of primary BC or at the diagnosis of advanced or recurrent BC, (ii) age between 20 and 65 years at the time of diagnosis, (iii) more than 1 year had passed from the time of an operation for primary BC or a diagnosis of advanced or recurrent cancer and (iv) performance status was 0 or 1. Subjects were divided into four groups: three groups according to adjuvant therapy (Group A: local treatment only, Group B: local treatment plus endocrine therapy, Group C: local treatment plus chemotherapy) and one group with advanced or recurrent BC (Group D). Local treatment included operation with or without adjuvant radiation therapy. Group C also included patients who underwent adjuvant endocrine therapy followed by chemotherapy. One hundred patients in each group and 400 patients in total were scheduled to enroll.
Questionnaire design and content
We developed original questionnaires after considering existing reports about cancer-related issues at other cancer treatment sites in Japan (17) . The questionnaire included patient's background, cancer treatment received, type of occupation, changes in work situation (e.g. quit, duration of absence, shortened work time), relationship with workplace (e.g. 'Do you receive understanding and support from your current employer?') and any anxiety about working (e.g. 'Are you anxious about your current work because of cancer?') and income (e.g. Asking about annual income at the time of diagnosis and present). For the occupational variable, patients were asked about the type of employment at diagnosis and at present, and their responses were categorized as 'self-employed', 'occupying in family business', 'publicly employed', 'regular employed (permanently employed)', 'non-regular employed (included part-time workers, temporary workers, contract-based workers and dispatched workers)' and 'executive of an organization'. Group D patients were asked about their work situation after the diagnosis of advanced or recurrent cancer. Quit rate was calculated by dividing the number of patients who left work by the number of patients who worked at that time.
Statistical analysis
Questionnaire results were collated and analyzed using descriptive statistics. Data were analyzed by the Kruskal-Wallis test to investigate the difference of absence weeks between combination (breast and axilla surgery) operation methods and the Mann-Whitney test to investigate the difference of it between the two groups of the methods of immediate reconstruction surgery, breast and axilla surgery. The Wilcoxon rank sum test was used to investigate the trend between each group. All analyses were calculated using a Stata computer program (Ver.12). Values of P or trend P < 0.05 were considered statistically significant. This study was approved by the Institutional Review Board of Aichi Cancer Center Hospital (approved No. 2014-1-015).
Results
We distributed the questionnaire to 425 patients and 283 patients returned it. The return rate of questionnaires was 67%. We excluded 4 patients who did not meet the inclusion criteria; therefore, the study included 279 patients (62, 79, 92 and 46 patients in Groups A, B, C and D, respectively).
Patient background
All patients were female ( Table 1 ). The mean age of all patients was 47.8 years at diagnosis and 54.9 years at present. The percentage of patients in each group increased with the complexity of treatment: 44% of patients in Group A were Stage 0, 58% of patients in Group B were Stage I and 35% of patients in Group C were Stage II. Of the 46 patients in Group D, 24% had advanced cancer at the time of diagnosis and 72% were diagnosed as recurrent cancer. Among all patients, 41 patients (14.7%) had dependent family members at the time of diagnosis.
At the time of diagnosis, most patients were a non-regular employee (36%), followed by regular employee (27%), publicly employed (14%), occupying in family business (10%) and selfemployed (7%) ( Table 1) .
Results in primary treatment groups (Groups A, B and C)
In the primary treatment group (Groups A, B and C; n = 233), 43 patients (18.5%) quit their job during or after treatment. Most (7.5%) patients had quit their jobs at the time of diagnosis, compared with those who quit while undergoing chemotherapy (5.6%) or at the time of operation (4.9%). One hundred and twenty-seven patients (57%) were absent from work at the time of operation, compared with those absent due to chemotherapy (33%) and radiation therapy (28%) (Fig. 1) .
The quit rate among occupations was highest in non-regular employees (32%), followed by regular employees (21%). Among the quit categories, 88% (n = 51) of patients voluntary retired (resignation) and 6.9% (n = 4) were dismissed (Fig. 2) .
Among the patients who were absent from their jobs for treatment, the duration of absence varied according to the type of operation ( Table 2 ). The median absence was significantly different between the types of breast surgery (breast-conserving surgery, 3 weeks, compared with mastectomy, 6 weeks; P = 0.008). In contrast, there was no significant difference in median absence between the types of axilla surgery: sentinel lymph node biopsy, 4 weeks, compared with axillary lymph node dissection, 4 weeks; P = 0.11. For reconstruction surgery immediately after mastectomy, the median duration of absence differed between tissue expander/silicone breast implant (TE/SBI) and autologous reconstruction (AR): TE/SBI was 4 weeks compared with tissue AR, which was 8 weeks, but the difference was not significant. The median durations of absence during radiation therapy and chemotherapy were 6 weeks (3-16 weeks) and 22 weeks (4-48 weeks), respectively.
Quit rates of the workplace in which patients worked at the time of diagnosis, cancer report rates for the workplace and change of income according to each treatment group are presented in Table 3 . The majority of patients (81%) wanted to continue working at the same workplace where they worked at the time of diagnosis; the quit rate was highest in Group C (30%), followed by Group B (20%) and Group A (13%) (trend P = 0.001). The quit rate increased with complexity of the treatment, although these rates included some patients who changed their jobs or retired due to age, which suggested reasons other than BC. For the total patient population, 29 patients (12%) did not tell their employer about their cancer, and the report rates did not correlate with treatment complexity. The majority of patients in Group A (77%) and Group B (71%) responded 'no change' to questions about income, however, 47% of Group C responded 'decreased' to questions about income. 
Results from advanced and recurrent BC group (Group D)
In the advanced and recurrent BC group (Group D; n = 46), patients were asked about their working situation after the diagnosis of advanced or recurrent BC. Sixteen patients (35%) quit their job during treatment; the quit rate was lowest during endocrine therapy (3.3%) and did not differ significantly at the time of operation (11%), during radiation therapy (14%) or during chemotherapy (11%). The quit rate was highest (6.8%) during treatment compared with that at the time of diagnosis of advanced or recurrent BC. The majority of patients (78%) wanted to continue working at the same workplace where they worked at the time of diagnosis (Table 3 ).The quit rate of the workplace where the patient worked at the time of diagnosis was 35%, and 13% of the patients did not tell their employer about their cancer. Forty-eight percent of the patients responded 'no change' to questions about income and 39% of the patients responded 'decreased' to questions about income.
Results for current workers (Groups A, B, C and D)
Among all current workers in Groups A, B, C and D (n = 54, 73, 76 and 34, respectively), the majority of patients responded that they wanted to continue working at their current workplace (Table 4) . For primary treatment groups, the rates of the patients who had anxiety about working correlated with complexity of treatment (trend P = 0.004:30, 26 and 9% in Groups C, B, and A, respectively). For Group D, more than half (62%) of the patients have anxiety about current working and felt a lack of support at their workplace than did patients in the adjuvant therapy group. 
Discussion
This is the first comprehensive report about the employment status of Japanese BC patients. In the primary treatment groups, the quit rate was highest at the time of diagnosis, and the patients whose cancer was treated heavily had higher quit rates and experienced more anxiety about continuing to work. Patients in this study were divided into groups according to three typical adjuvant treatment courses and advanced settings to determine if the complexity of treatment regimens might affect the patient's employment situation. As we suspected, the frequencies of quit rate and anxiety increased with complexity of treatment regimen. This classification is useful for the daily clinical situation and is also helpful when systematic employment support plans are constructed for patients.
Islam et al. reported in their systematic review that the return to work rate was significantly different between each country (14) . This difference might be predicated on differences in healthcare systems and social insurance programs across countries. Furthermore, the treatment of BC has changed dramatically in the past few decades and the methods of treatment including the duration of hospitalization (18) or frequency of visiting hospital may differ between countries or hospitals. Therefore, it is important to understand the situation of local patients opportunely. This study revealed detailed information about the employment status of patients in the current clinical setting.
Results in our primary treatment groups demonstrated that the quit rate was highest at the time of diagnosis, which may indicate that consultation about work status is necessary immediately after diagnosis for these patients. The patients treated heavily had higher quit rates and experienced more anxiety about working; therefore, more careful consultation is needed for these patients. For advanced or recurrent BC patients (Group D), their types of treatment differed widely; therefore, it is difficult to compare their employment status with other groups. However, as this group was obviously highest in anxiety about working, and quit timing was not associated with treatment, it seems they may need continuous support throughout their treatment course.
Awareness of physicians and medical teams about employment of cancer patients are necessary to improve the situation. In a survey of physicians involved in BC treatment who were asked about their thoughts on patients returning to work (19) , almost all physicians responded that patients were able to work during endocrine therapy (96.2%) or radiation therapy (94.6%). The survey was conducted in the same area as our institution, however, there was a discrepancy between their results which represent physician's thoughts and our results which represent patients' experiences. Our results indicated only 35.1% of the patients could continue working as usual during radiation therapy, and 73.1% of the patients could do so during endocrine therapy. These results indicate that there are differences in recognition of treatment and working status between physicians and patients. Our study may help to resolve those differences and promote an understanding between the medical team and the patient's employer.
Our study had some limitations. First, subjects were BC patients only, therefore, the results cannot be compared with the general population. According to the Japanese Ministry of Health, Labour and Welfare (20), in 2016, among working women, 56.3% were non-regular employees and their quit rate per year was 11.8%. In our study, non-regular employees constituted 36% of the subjects, which was relatively fewer than in the general population, and their quit rate was 32%, which was higher than in the general population. However, our results did not indicate the quit rate per year, so it is difficult to demonstrate validity for comparison with the general population. Second, the questionnaire included the clause asking form of quitting job (e.g. resignation, dismissed); however, it did not include the clause asking the reason of quitting job. Therefore, we could not distinguish the patients who quit the job for the reason which unrelated with their disease. Third, all our results were based on a self-reported questionnaire, which might produce some results that differ with results collected through more objective methodologies such as administrative database.
In conclusion, this study revealed detailed information about the employment status of Japanese BC patients in the current clinical setting. Results from the primary treatment groups in which the quit rate was highest at the time of diagnosis suggest that consultation with patients about their work status is necessary immediately after diagnosis. In addition, the patients treated heavily had higher quit rates and experienced more anxiety about working, therefore, more carful consultation is needed according to the heaviness of treatment. This study provides useful information about working conditions for Japanese BC patients who are employed.
